Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 84.19 kCr |
| Price/Earnings (Trailing) | 47.39 |
| Price/Sales (Trailing) | 5.87 |
| EV/EBITDA | 24.72 |
| Price/Free Cashflow | 51.99 |
| MarketCap/EBT | 38.9 |
| Enterprise Value | 92.23 kCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 14.34 kCr |
| Rev. Growth (Yr) | 10.1% |
| Earnings (TTM) | 1.8 kCr |
| Earnings Growth (Yr) | 7.6% |
Profitability | |
|---|---|
| Operating Margin | 16% |
| EBT Margin | 15% |
| Return on Equity | 11.61% |
| Return on Assets | 6.26% |
| Free Cashflow Yield | 1.92% |
Growth & Returns | |
|---|---|
| Price Change 1W | -1.9% |
| Price Change 1M | -4% |
| Price Change 6M | -21.8% |
| Price Change 1Y | -13.8% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -12.68 kCr |
| Cash Flow from Operations (TTM) | 2.41 kCr |
| Cash Flow from Financing (TTM) | 10.29 kCr |
| Cash & Equivalents | 327.77 Cr |
| Free Cash Flow (TTM) | 1.95 kCr |
| Free Cash Flow/Share (TTM) | 47.31 |
Balance Sheet | |
|---|---|
| Total Assets | 28.81 kCr |
| Total Liabilities | 13.28 kCr |
| Shareholder Equity | 15.53 kCr |
| Current Assets | 8.29 kCr |
| Current Liabilities | 7.1 kCr |
| Net PPE | 2.93 kCr |
| Inventory | 1.97 kCr |
| Goodwill | 6.49 kCr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.29 |
| Debt/Equity | 0.54 |
| Interest Coverage | 2.15 |
| Interest/Cashflow Ops | 5.1 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 1 |
| Dividend Yield | 0.05% |
| Shares Dilution (1Y) | 0.10% |
Balance Sheet: Strong Balance Sheet.
Size: It is among the top 200 market size companies of india.
Growth: Good revenue growth. With NA% growth over past three years, the company is going strong.
Profitability: Recent profitability of 13% is a good sign.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Smart Money: Smart money has been increasing their position in the stock.
Momentum: Stock is suffering a negative price momentum. Stock is down -4% in last 30 days.
Balance Sheet: Strong Balance Sheet.
Size: It is among the top 200 market size companies of india.
Growth: Good revenue growth. With NA% growth over past three years, the company is going strong.
Profitability: Recent profitability of 13% is a good sign.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Smart Money: Smart money has been increasing their position in the stock.
Momentum: Stock is suffering a negative price momentum. Stock is down -4% in last 30 days.
Investor Care | |
|---|---|
| Dividend Yield | 0.05% |
| Dividend/Share (TTM) | 1 |
| Shares Dilution (1Y) | 0.10% |
| Earnings/Share (TTM) | 43.04 |
Financial Health | |
|---|---|
| Current Ratio | 1.17 |
| Debt/Equity | 0.54 |
Technical Indicators | |
|---|---|
| RSI (14d) | 46.94 |
| RSI (5d) | 43.08 |
| RSI (21d) | 46.43 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Updated May 4, 2025
The stock has experienced a daily loss of 3.74% and a decline of 6.34% over the past six months.
Mankind Pharma's shares have fluctuated between ₹1910.1 and ₹3050 over the past 52 weeks, indicating volatility.
Compared to competitor Sun Pharmaceutical, Mankind has exhibited weaker gains across multiple time frames.
Summary of Mankind Pharma's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Management provided a positive outlook for Mankind Pharma, highlighting a robust revenue growth trajectory. For Q3 FY26, overall revenue increased by 11.5% year-on-year, reaching INR 3,567 crores. In the first nine months of FY26, revenue grew 18.7% year-on-year to INR 10,835 crores with an adjusted EBITDA margin of 24.9%.
Key forward-looking points include:
Domestic business growth: The domestic sector recorded an 11.1% growth year-on-year, driven by a strong performance in chronic therapies, which grew 16.7% in cardio and 14.4% in antidiabetes.
Brand performance improvement: The number of INR 200 crore brand families increased from 11 to 13, and INR 50 crore brands rose from 49 to 51 within a year.
Digital transformation: Initiatives in digital transformation are expected to enhance organizational agility and efficiency, fostering sustainable growth.
Focus on chronic therapies: Mankind's chronic contribution improved to 36.7% of revenue, up 200 basis points year-on-year, with ambition to strengthen this further.
Market strategy: Despite challenges in acute segments, management expects gradual recovery through strategical market initiatives and stabilizing their workforce.
E-commerce and OTC growth: E-commerce channels reported over 40% growth, increasing their share of OTC sales, which management views as a significant opportunity.
In summary, Mankind Pharma's management expresses confidence in navigating challenges and achieving consistent long-term growth driven by strong operational and strategic initiatives.
Understand Mankind Pharma ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| Ramesh Juneja Family Trust (Held in the name of Ramesh Juneja, Managing Trustee) | 20.19% |
| Rajeev Juneja Family Trust (Held in the name of Rajeev Juneja, Managing Trustee) | 19.36% |
| Prem Sheetal Family Trust (Held in the name of Arora Family Private Limited, Trustee) | 14.96% |
| SHEETAL ARORA | 4.67% |
| PUJA JUNEJA | 2.79% |
| NPS TRUST A/C - LIC PENSION FUND - UPS - CG SCHEME |
Detailed comparison of Mankind Pharma against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.11 LCr | 58.94 kCr | +6.20% | +2.20% | 37.66 | 6.98 | - | - |
| DIVISLAB | Divi's Lab | 1.67 LCr |
Comprehensive comparison against sector averages
MANKIND metrics compared to Pharmaceuticals
| Category | MANKIND | Pharmaceuticals |
|---|---|---|
| PE | 48.22 | 33.98 |
| PS | 5.98 | 4.69 |
| Growth | 19.3 % | 10.8 % |
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. Mankind Pharma Limited was founded in 1986 and is based in New Delhi, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Buy |
| SMA 20 Signal | Sell |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
MANKIND vs Pharmaceuticals (2024 - 2026)
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Analysts recommend Mankind Pharma shares as a fundamental 'buy' with a target price of ₹2,750.
Mankind Pharma's stock has shown a positive return of 4.04% over the past year.
Analyst / Investor Meet • 18 Feb 2026 Please find attached intimation of participation in Investor Conference |
General • 16 Feb 2026 Please find attached disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 |
Earnings Call Transcript • 09 Feb 2026 Please find enclosed herewith the transcript of the investor conference call for Q3 & 9M FY26 held on February 3, 2026. |
General • 09 Feb 2026 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |
Newspaper Publication • 04 Feb 2026 Please find attached intimation regarding newspaper advertisement - Unaudited Financial Results of the Company for Q3 FY26 |
• 04 Feb 2026 |
This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.
Q1: "Sir, on the prescription side, where the industry growth itself is a bit slow at about 4% and as a part of acute therapy that forms a considerable portion for the Mankind portfolio. So how we sort of intend to grow in this therapy?"
A: I acknowledge the challenge in the anti-infectives segment. Our focus remains on building relationships and enhancing our teams' understanding and presence. While the anti-infectives have been muted, we expect gradual improvements as our teams stabilize and relationships mature in the coming quarters.
Q2: "On the therapy level, respiratory also, like compared to the industry, the growth has been bit soft at 7.6%. If you could call out any factors on this therapy?"
A: Our respiratory growth has faced challenges, particularly in cough therapy. However, we've seen strong performance in our inhaler portfolio. We're re-evaluating strategies within the cough segment, which should yield better results next quarter.
Q3: "The CFO to EBITDA ratio has become very strong. If you could highlight factors driving this and how sustainable this is going forward?"
A: The significant improvement in our CFO to EBITDA ratio, now at 93%, is due to optimized working capital and the effective realization of government receivables. While it's a strong quarter, we expect this ratio to normalize as we move forward.
Q4: "Can you split the export revenues between BSV and organic growth for us?"
A: In Q3, Mankind's exports' growth is attributed mainly to BSV consolidation. Organic growth has been mid-single digits while BSV is contributing significantly, surpassing previous performance metrics.
Q5: "What percentage of our field force, including managers, would be new to Mankind in recent months?"
A: Approximately 20%-25% of our field force is new, having joined within the last 12-15 months. This transition took time as our unique culture needed effective communication and integration for success, especially in our relationship-driven segments.
| 2.61% |
| POONAM JUNEJA | 2.56% |
| ARJUN JUNEJA | 1.98% |
| RAMESH JUNEJA | 1.66% |
| RAJEEV JUNEJA | 1.57% |
| SBI ARBITRAGE OPPORTUNITIES FUND | 1.5% |
| NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA LARGE CAP FUND | 1.29% |
| AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL FUND | 1.17% |
| EKLAVYA JUNEJA | 0.94% |
| CHANAKYA JUNEJA | 0.94% |
| MISHKA ARORA | 0.72% |
| RIA CHOPRA JUNEJA | 0.31% |
| AYUSHI JUNEJA SIKRI | 0% |
| PUSHPA RANI AGGARWAL | 0% |
| Rajeev Mohan Agarwal | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
| 10.75 kCr |
| +4.70% |
| +6.10% |
| 67.45 |
| 15.55 |
| - |
| - |
| TORNTPHARM | Torrent Pharmaceuticals | 1.43 LCr | 12.65 kCr | +6.30% | +35.40% | 62.97 | 11.31 | - | - |
| CIPLA | Cipla | 1.07 LCr | 29.37 kCr | -3.60% | -9.20% | 23.61 | 3.65 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.07 LCr | 36.09 kCr | +9.90% | +10.00% | 19.18 | 2.97 | - | - |
| AUROPHARMA | Aurobindo Pharma | 68.04 kCr | 33.73 kCr | +2.60% | +3.20% | 19.51 | 2.02 | - | - |
| ALKEM | Alkem Lab | 64.59 kCr | 14.78 kCr | -6.00% | +13.40% | 27.24 | 4.37 | - | - |
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
| -4.4% |
| 3,028 |
| 3,167 |
| 3,113 |
| 2,813 |
| 2,339 |
| 2,330 |
| Profit Before exceptional items and Tax | -1.6% | 612 | 622 | 537 | 494 | 847 | 664 |
| Exceptional items before tax | - | -106.59 | 0 | 0 | 0 | 0 | 0 |
| Total profit before tax | -18.7% | 506 | 622 | 537 | 494 | 847 | 664 |
| Current tax | 23.4% | 154 | 125 | 111 | 158 | 168 | 139 |
| Deferred tax | -167.4% | -58.76 | -21.35 | -15.07 | -44.95 | 22 | -14.15 |
| Total tax | -8.7% | 95 | 104 | 96 | 113 | 190 | 125 |
| Total profit (loss) for period | -20.4% | 414 | 520 | 445 | 385 | 659 | 543 |
| Other comp. income net of taxes | -77.5% | 5.95 | 23 | -0.76 | 11 | -2.2 | -3.1 |
| Total Comprehensive Income | -22.7% | 420 | 543 | 444 | 395 | 657 | 540 |
| Earnings Per Share, Basic | -21.9% | 9.9 | 12.39 | 10.62 | 9.45 | 16.31 | 13.39 |
| Earnings Per Share, Diluted | -21.9% | 9.89 | 12.38 | 10.6 | 9.44 | 16.28 | 13.37 |
| 378 |
| 318 |
| 270 |
| Other expenses | 7.7% | 2,207 | 2,049 | 1,884 |
| Total Expenses | 5.7% | 7,685 | 7,272 | 6,727 |
| Profit Before exceptional items and Tax | 2% | 2,306 | 2,260 | 1,563 |
| Total profit before tax | 2% | 2,306 | 2,260 | 1,563 |
| Current tax | 12.7% | 470 | 417 | 292 |
| Deferred tax | -358.9% | -48.19 | 20 | 23 |
| Total tax | -3.2% | 422 | 436 | 315 |
| Total profit (loss) for period | 6.7% | 1,945 | 1,823 | 1,248 |
| Other comp. income net of taxes | 151.7% | 4.98 | -6.7 | -4.86 |
| Total Comprehensive Income | 7.3% | 1,950 | 1,817 | 1,243 |
| Earnings Per Share, Basic | 110.7% | 94.8 | 45.52 | 31.16 |
| Earnings Per Share, Diluted | 110.6% | 94.63 | 45.45 | 31.16 |
| Debt service coverage ratio | - | 055 | - | - |
| Interest service coverage ratio | - | 0.0588 | - | - |
| -0.3% |
| 1,935 |
| 1,941 |
| 1,802 |
| 1,811 |
| 1,827 |
| 1,436 |
| Capital work-in-progress | 30% | 248 | 191 | 121 | 113 | 92 | 438 |
| Investment property | - | 0 | 0 | 5.24 | 5.27 | 5.3 | 5.32 |
| Goodwill | 0% | 9.96 | 9.96 | 6.56 | 6.56 | 6.56 | 6.56 |
| Non-current investments | 1.2% | 15,308 | 15,125 | 2,294 | 2,191 | 2,160 | 2,041 |
| Loans, non-current | -51.1% | 5.14 | 9.46 | 36 | 8.74 | 0 | 0 |
| Total non-current financial assets | 0.3% | 15,324 | 15,280 | 2,345 | 2,216 | 2,217 | 2,075 |
| Total non-current assets | 1% | 19,214 | 19,032 | 5,991 | 5,859 | 5,877 | 5,759 |
| Total assets | 4.3% | 24,862 | 23,828 | 13,260 | 11,418 | 10,564 | 9,371 |
| Borrowings, non-current | -24.5% | 3,734 | 4,946 | 4.47 | 5.95 | 7.31 | 3.23 |
| Total non-current financial liabilities | -24.5% | 3,734 | 4,946 | 4.47 | 5.95 | 7.31 | 3.23 |
| Provisions, non-current | 2.4% | 129 | 126 | 119 | 112 | 104 | 89 |
| Total non-current liabilities | -24.1% | 3,869 | 5,097 | 227 | 201 | 279 | 168 |
| Borrowings, current | 52.3% | 3,514 | 2,308 | 203 | 2.62 | 2.43 | 1.46 |
| Total current financial liabilities | 41.6% | 4,804 | 3,394 | 1,528 | 1,035 | 1,059 | 983 |
| Provisions, current | 5.8% | 584 | 552 | 388 | 373 | 332 | 295 |
| Current tax liabilities | - | 12 | 0 | 88 | 42 | 86 | 43 |
| Total current liabilities | 34% | 5,482 | 4,092 | 2,100 | 1,593 | 1,614 | 1,419 |
| Total liabilities | 1.8% | 9,351 | 9,188 | 2,473 | 1,794 | 1,893 | 1,587 |
| Equity share capital | 0% | 41 | 41 | 40 | 40 | 40 | 40 |
| Total equity | 5.9% | 15,511 | 14,640 | 10,787 | 9,624 | 8,671 | 7,784 |
| Total equity and liabilities | 4.3% | 24,862 | 23,828 | 13,260 | 11,418 | 10,564 | 9,371 |
| - |
| Purchase of other long-term assets | - |
| Cash receipts from repayment of advances and loans made to other parties | -88.9% |
| Interest received | 130.4% |
| Other inflows (outflows) of cash | 146.3% |
| Net Cashflows From Investing Activities | -531% |
| Proceeds from issuing shares | - |
| Proceeds from borrowings | 49220.8% |
| Repayments of borrowings | 19083.3% |
| Payments of lease liabilities | 689.5% |
| Interest paid | 6677.3% |
| Other inflows (outflows) of cash | - |
| Net Cashflows from Financing Activities | 101154% |
| Effect of exchange rate on cash eq. | -198.2% |
| Net change in cash and cash eq. | -122.8% |
Press Release / Media Release • 03 Feb 2026 Press Release for Q3 FY26 |